This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cerus Announces First INTERCEPT Blood System Customer In Turkey

Cerus Corporation (NASDAQ: CERS) announced today that Hemakim, Cerus’ distributor for Turkey, has signed an agreement with the Florence Nightingale Hospital, a leading medical center in Turkey, to supply the INTERCEPT Blood System for platelets and plasma.

“With the adoption of the INTERCEPT Blood System, we know we are doing everything in our power to provide patients with safe and effective blood products, consistent with our mission to use innovative products to continuously improve patient care,” said Dr. Hulya Bilgen, associate professor and director of the Florence Nightingale Transfusion Center. “We strive to provide our patients and their families with the best the world can offer, with service from a qualified and experienced clinical staff.”

“We are extremely proud that the INTERCEPT system meets Florence Nightingale Hospital’s demanding standards for healthcare technologies, and we share the Hospital’s passion for patient safety,” said Caspar Hogeboom, president of Cerus Europe. “Including Turkey, customers in 18 countries have chosen the INTERCEPT Blood System to protect patients from transfusion-transmitted diseases.”

The Florence Nightingale Hospital Group, based in Istanbul, Turkey, offers patient-centered and specialized healthcare by integrating education, research and technology with clinical care. The group was founded in 1989, under the body of Turkish Cardiology Foundation, as the first cardiovascular disease hospital in the region. Today, with four general hospitals, a medical center, a teaching hospital, a clinical research center and a Hi-Tech hospital, the Florence Nightingale Hospital Group is one of the largest and most reputed hospitals in Europe and the Middle East.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,627.55 -62.31 -0.35%
S&P 500 2,104.34 +0.50 0.02%
NASDAQ 5,136.6530 +8.3720 0.16%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs